Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intersect Ent Inc
(NQ:
XENT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 12, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intersect Ent Inc
< Previous
1
2
Next >
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization
January 25, 2022
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT Reports Third Quarter 2021 Financial Results
November 02, 2021
From
Intersect ENT, Inc.
Via
Business Wire
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
October 28, 2021
From
Intersect ENT®, Inc.
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, LMRK, XENT, JAX; Shareholders are Encouraged to Contact the Firm
September 13, 2021
NEW YORK, NY / ACCESSWIRE / September 13, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Inovalon Holdings, Inc. (NASDAQ: INOV)...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, GTS, XONE, XENT; Shareholders are Encouraged to Contact the Firm
September 04, 2021
NEW YORK, NY / ACCESSWIRE / September 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Inovalon Holdings, Inc. (NASDAQ:INOV)...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CSOD, XENT, FFWM, RIVE; Shareholders are Encouraged to Contact the Firm
August 19, 2021
NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cornerstone OnDemand, Inc. (NASDAQ:CSOD)...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
INVESTIGATION: Halper Sadeh LLP Investigates NLOK, XENT, NWHM; Shareholders are Encouraged to Contact the Firm
August 12, 2021
NEW YORK, NY / ACCESSWIRE / August 12, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: NortonLifeLock Inc. (NASDAQ:NLOK) concerning...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021
August 12, 2021
Upgrades According to Northland Capital Markets, the prior rating for Points International Ltd
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021
August 09, 2021
Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
August 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
COVID-19
INTERSECT ENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intersect ENT - XENT
August 06, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
Why Intersect ENT Shot 12% Higher on Friday
August 06, 2021
It's official: A big peer is buying out the specialty medical device maker.
Via
The Motley Fool
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
August 06, 2021
From
Halper Sadeh LLP
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
August 06, 2021
Gainers SCWorx (NASDAQ:WORX) shares moved upwards by 20.59% to $3.08 during Friday's regular session. The current volume of 16.2 million shares is 348.19% of SCWorx...
Via
Benzinga
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
August 06, 2021
Medtronic plc (NYSE:MDT)
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
August 06, 2021
Gainers Applied Molecular (NASDAQ:AMTI) shares increased by 19.38% to $35.54 during Friday's pre-market session. The market value of their outstanding shares is at $1....
Via
Benzinga
Intersect ENT: Q2 Earnings Insights
August 06, 2021
Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 24.62% year over year to ($0...
Via
Benzinga
Intersect ENT Reports Second Quarter 2021 Financial Results
August 06, 2021
From
Intersect ENT, Inc.
Via
Business Wire
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
July 26, 2021
From
Intersect ENT
Via
Business Wire
Earnings Scheduled For August 6, 2021
August 06, 2021
Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million....
Via
Benzinga
Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding
July 23, 2021
Intersect ENT Inc (NASDAQ: XENT) expects Q2 sales of approximately $27.3 million, slightly below the consensus estimate of $28.02 million. Record quarterly revenue from...
Via
Benzinga
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
July 23, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
July 22, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021
June 24, 2021
Upgrades Zelman upgraded the previous rating for Armstrong World Industries Inc (NYSE:
Via
Benzinga
Intersect ENT Insights: Return On Capital Employed
June 23, 2021
In Q1, Intersect ENT (NASDAQ:XENT) posted sales of $24.33 million. Earnings were up 7.66%, but Intersect ENT still reported an overall loss of $18.57 million. Intersect ENT...
Via
Benzinga
Intersect ENT Insights: Return On Capital Employed
June 07, 2021
In Q1, Intersect ENT (NASDAQ:XENT) posted sales of $24.33 million. Earnings were up 7.66%, but Intersect ENT still reported an overall loss of $18.57 million. In Q4, Intersect ENT...
Via
Benzinga
Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
May 20, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Recap: Intersect ENT Q1 Earnings
May 10, 2021
Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 5.56% year over year to ($0.51),...
Via
Benzinga
Intersect ENT Reports First Quarter 2021 Financial Results
May 10, 2021
From
Intersect ENT, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.